Development and validation of prognosis model of mortality risk in patients with COVID-19

Abstract This study aimed to identify clinical features for prognosing mortality risk using machine-learning methods in patients with coronavirus disease 2019 (COVID-19). A retrospective study of the inpatients with COVID-19 admitted from 15 January to 15 March 2020 in Wuhan is reported. The data of symptoms, comorbidity, demographic, vital sign, CT scans results and laboratory test results on admission were collected. Machine-learning methods (Random Forest and XGboost) were used to rank clinical features for mortality risk. Multivariate logistic regression models were applied to identify clinical features with statistical significance. The predictors of mortality were lactate dehydrogenase (LDH), C-reactive protein (CRP) and age based on 500 bootstrapped samples. A multivariate logistic regression model was formed to predict mortality 292 in-sample patients with area under the receiver operating characteristics (AUROC) of 0.9521, which was better than CURB-65 (AUROC of 0.8501) and the machine-learning-based model (AUROC of 0.4530). An out-sample data set of 13 patients was further tested to show our model (AUROC of 0.6061) was also better than CURB-65 (AUROC of 0.4608) and the machine-learning-based model (AUROC of 0.2292). LDH, CRP and age can be used to identify severe patients with COVID-19 on hospital admission.

[1]  A. Harky,et al.  The role of biomarkers in diagnosis of COVID-19 – A systematic review , 2020, Life Sciences.

[2]  L. Mombaerts,et al.  An interpretable mortality prediction model for COVID-19 patients , 2020, Nature Machine Intelligence.

[3]  G. Banfi,et al.  Routine blood tests as a potential diagnostic tool for COVID-19 , 2020, Clinical chemistry and laboratory medicine.

[4]  Yaling Shi,et al.  A Tool to Early Predict Severe Corona Virus Disease 2019 (COVID-19) : A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Fang Liu,et al.  Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 , 2020, Journal of Clinical Virology.

[6]  G. Heinze,et al.  Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal , 2020, BMJ.

[7]  Bei Cheng,et al.  Clinical features predicting mortality risk in older patients with COVID-19 , 2020, Current medical research and opinion.

[8]  L. Wang,et al.  C-reactive protein levels in the early stage of COVID-19 , 2020, Médecine et Maladies Infectieuses.

[9]  C. Tong,et al.  Lactate dehydrogenase, a Risk Factor of Severe COVID-19 Patients , 2020, medRxiv.

[10]  Jian-feng Xie,et al.  Development and external validation of a prognostic multivariable model on admission for hospitalized patients with COVID-19 , 2020, medRxiv.

[11]  Yaling Shi,et al.  A Tool to Early Predict Severe 2019-Novel Coronavirus Pneumonia (COVID-19) : A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China , 2020, medRxiv.

[12]  Yu Shi,et al.  Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan , 2020, Critical Care.

[13]  Yu Zhou,et al.  Predicting COVID-19 malignant progression with AI techniques , 2020, medRxiv.

[14]  Qiu Zhao,et al.  Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Wenzhen Zhu,et al.  Clinical and High-Resolution CT Features of the COVID-19 Infection: Comparison of the Initial and Follow-up Changes , 2020, Investigative radiology.

[16]  X. Qi,et al.  Machine learning-based CT radiomics model for predicting hospital stay in patients with pneumonia associated with SARS-CoV-2 infection: A multicenter study , 2020, medRxiv.

[17]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[18]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[19]  Nuno Ferreira,et al.  Estimation of risk factors for COVID-19 mortality - preliminary results , 2020, medRxiv.

[20]  Ting Yu,et al.  Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.

[21]  Jian Sun,et al.  ACP risk grade: a simple mortality index for patients with confirmed or suspected severe acute respiratory syndrome coronavirus 2 disease (COVID-19) during the early stage of outbreak in Wuhan, China , 2020, medRxiv.

[22]  Jiyuan Zhang,et al.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.

[23]  Chuan Qin,et al.  Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[25]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[26]  E. Shin,et al.  Predictors of mortality in Middle East respiratory syndrome (MERS) , 2017, Thorax.

[27]  T. Kishaba,et al.  Staging of Acute Exacerbation in Patients with Idiopathic Pulmonary Fibrosis , 2014, Lung.

[28]  D. Christiani,et al.  Plasma C-reactive protein levels are associated with improved outcome in ARDS. , 2009, Chest.

[29]  O. Tsang,et al.  Outcomes and Prognostic Factors in 267 Patients with Severe Acute Respiratory Syndrome in Hong Kong , 2003, Annals of Internal Medicine.